A new international study has found that some people with HIV can keep the virus under control for years without daily medication. The work points to a future where the immune system, not pills, does most of the heavy lifting.
For more than three decades, the standard message about HIV has been clear: with the right drugs, the virus can be controlled, but not cured. People who stop taking their daily medication almost always see the virus roar back within weeks.
Now, new research suggests that for a small but important group of people, the story can be different.
An international team led by scientists at Aarhus University Hospital and Aarhus University has shown that some patients can keep HIV in check for years after stopping antiretroviral therapy, thanks to a powerful one-two punch from their own immune systems. The findings, published in Nature Immunology, could help reshape long-term HIV care and bring researchers closer to treatments that do not require lifelong daily pills.
Modern HIV drugs are highly effective. They suppress the virus to undetectable levels, allow people to live long, healthy lives, and prevent transmission, including from mothers to their babies. But the virus is not gone; it hides in reservoirs inside cells. If treatment stops, the virus typically rebounds quickly, with high levels detectable in the blood within two to three weeks.
That challenge has driven researchers for years to look for ways to shift control of HIV from medication to the immune system itself.
In a series of clinical trials, the Aarhus-led team gave people living with HIV experimental treatment and then, under close medical supervision, stopped their regular HIV medication. In most participants, the virus eventually returned. But in about 10% to 20% of cases, something remarkable happened: the virus stayed under control without drugs.
In these individuals, the immune system seemed to take over the role usually played by antiretroviral therapy. The new study dug into why.
The researchers focused on two major arms of the immune system: antibodies, which can recognize and neutralize viruses circulating in the blood, and T cells, which can find and destroy infected cells. The team’s work shows that in the patients who maintained control of HIV, these two components did not just act independently; they worked together in a complementary way, targeting different features of the virus and making it much harder for HIV to escape.
The study followed three patients closely for up to seven years after they stopped daily HIV medication. Two of them have remained off treatment the entire time and are still healthy by all clinical measures, with the virus held in check by their immune systems. A third patient managed without drugs for about two-and-a-half years before the virus returned.
When that rebound happened, the virus had mutated in ways that allowed it to evade both the antibodies and the T cells that had previously kept it under control. While this was a setback for the individual patient, it gave the scientists important clues about how and why the immune control works — and how it can fail.
The work is translational research, meaning it moves back and forth between basic science and clinical care, with the goal of turning laboratory insights into real-world treatments. The study’s full title, “Autologous neutralizing antibodies and polyfunctional T cells contribute to long-term HIV-1 post-intervention control,” reflects that focus on the combined role of different immune responses.
The next step for the team is to figure out how to make this kind of durable immune control possible for many more people.
Right now, only about 10% to 20% of patients in these trials have been able to stop medication without a viral rebound, according to corresponding author Ole Schmeltz Søgaard, a professor in the Department of Infectious Diseases at Aarhus University Hospital and the Department of Clinical Medicine at Aarhus University.
The researchers want to understand, in detail, what is special about their immune systems and then design therapies that can reproduce those conditions in others.
One strategy will be to test existing immune-boosting treatments that are already used in other diseases, such as certain forms of cancer immunotherapy. These therapies are designed to strengthen or fine-tune the body’s own defenses, and they could potentially be repurposed to enhance the specific antibodies and T cell responses that seem to matter most in HIV control.
If scientists can move from a small minority of patients to a reliable, widely applicable approach, the impact could be enormous.
For people in high-income countries, daily HIV pills are usually accessible, and treatment has turned HIV into a manageable chronic condition. But in many parts of the world, lifelong therapy is not always realistic. Barriers include cost, limited health care infrastructure, drug supply interruptions and the difficulty of staying on daily medication for decades.
A short-term treatment that trains the immune system to keep HIV in check on its own could transform care in those settings. It could also ease the burden for people everywhere who must now plan their lives around a strict medication schedule.
The study was carried out in collaboration with research groups in Germany, the United States, Canada, Switzerland and the UK, including teams at Johns Hopkins University, The Rockefeller University, Harvard University, Weill Cornell Medicine, the University of Cologne, Charité – Universitätsmedizin Berlin, Imperial College London, Université de Montréal, the University of Lausanne and Odense University Hospital.
The new findings do not mean that people with HIV can safely stop their medication on their own. The patients in the study were carefully selected, closely monitored and treated within controlled clinical trials. For now, experts stress that anyone living with HIV should continue to take their prescribed drugs unless they are part of a supervised research study.
But the work offers a glimpse of a different future: one where HIV is not just suppressed by daily pills, but held in permanent check by the body’s own defenses.
Source: Aarhus University Hospital